Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JOURNEY: Tezepelumab for COPD Exacerbation Reduction
jRCT2031250025Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of tezepelumab in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Annualised rate of moderate or severe COPD exacerbations up to 76 weeks. Started May 2025; status: recruiting.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2031250025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250025.